Off Patent
February 2027

Lexiscan

regadenoson

Astellas Pharma US Inc

Solution (intravenous) · NDA 022161

Last listed protection ends
February 2, 2027

The FDA lists 2 patents for Lexiscan, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 8,106,183
    Claims the drug substance
  2. Patent RE47301
    Claims the drug product